To include your compound in the COVID-19 Resource Center, submit it here.

A notch for tankyrase

NYU paper identifies new cancer opportunities for tankyrase inhibitors

New York University School of Medicine researchers have identified a multitude of tankyrase targets, including factors in the Notch and Wnt/β-catenin pathways, that offer new opportunities for tankyrase inhibitors in cancer.

In a Nature Communications study last month, the NYU team conducted proteomic screens in HEK cells with single- and double-knockout of tankyrase TRF1-interacting ankyrin-related ADP-ribose polymerase

Read the full 568 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE